Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Isarna Therapeutics Raises Euro 13 Million from New and Current Investors

Published: Wednesday, January 08, 2014
Last Updated: Wednesday, January 08, 2014
Bookmark and Share
Euro 13 million raised in equity from AT NewTec and MIG-managed funds.

Isarna Therapeutics GmbH has announced that it has raised Euro 13 million (USD 17.8 Mio) in equity from new private investor AT NewTec and current investors, MIG-managed funds.

Proceeds will be used to advance the company's pipeline of next generation oligonucleotides that inhibit various isoforms of TGF-β, a key molecular pathway implicated in mechanisms used by cancer cells to evade immune system detection and to aid in tumor proliferation.

"This financing supports our position as the leaders in utilizing TGF-β as a unique target for cancer immunotherapy and enables us to continue the rapid development of our pipeline toward the clinic," said Dr. Philippe Calais, Chief Executive Officer at Isarna Therapeutics. "We are fortunate to have the continued commitment from MIG, our largest shareholder, and welcome the new investment from AT NewTec.”

“MIG is convinced that an immunotherapy approach to treating cancer has the potential to change the paradigm of current standard of care,” added Dr. Matthias Kromayer, Managing Director of MIG Verwaltungs AG. “We have great confidence in both Isarna’s pioneering approach to leveraging TGF-β and the company’s management.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Isarna Announces Orphan Drug Designation for ISTH0036
Orphan drug designation in the European Union to treat advanced-stage glaucoma.
Saturday, May 23, 2015
Isarna Presents Positive Preclinical Results Supporting Development of ISTH0036
Oral and poster presentations given at ARVO 2015 annual conference.
Thursday, May 14, 2015
Isarna Initiates First-in-Human Phase I Trial for ISTH0036
Phase I trial designed to evaluate the safety and long-term tolerability of ISTH0036 in patients with advanced glaucoma.
Friday, April 17, 2015
Isarna Therapeutics Unveils New Selective TGF-beta Antagonist Program
First-in-human study in advanced-stage glaucoma to begin in 1H2015.
Friday, January 09, 2015
Isarna Therapeutics Raises €5.5 Million
Elizabeth Czerepak joins Company’s management team as Chief Financial Officer and Chief Business Officer.
Friday, April 25, 2014
Isarna Therapeutics Enters into a Strategic Manufacturing Agreement with Sanofi
Sanofi will manufacture clinical- and commercial-grade antisense oligonucleotide (ASO) compounds for Isarna.
Friday, January 10, 2014
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos